Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 11/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060621 | 0.85 | RAB9A (0.52) | QPCTPOLBNPC1RAB9AKMT2A | |
| SCHEMBL5060616 | 0.83 | QPCT (0.50) | QPCTPOLBNPC1RAB9AKMT2A | |
| SCHEMBL16667022 | 0.82 | QPCT (0.51) | QPCTPOLBNPC1RAB9AKMT2A | |
| SCHEMBL3634005 | 0.78 | QPCT (0.81) | QPCTPOLBNPC1RAB9AKMT2A | |
| SCHEMBL3632425 | 0.74 | QPCT (0.84) | QPCTPOLBNPC1RAB9AMAPT | |
| SCHEMBL5060652 | 0.73 | QPCT (0.48) | QPCTPOLBNPC1RAB9AKMT2A | |
| SCHEMBL13373434 | 0.72 | QPCT (0.53) | QPCTPOLBNPC1RAB9AKMT2A | |
| SCHEMBL31364144 | 0.72 | QPCT (0.53) | QPCTNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3629554 | 0.72 | QPCT (0.81) | QPCTNPC1RAB9AKMT2AMAPT | |
| SCHEMBL3633921 | 0.71 | QPCT (0.85) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885POLB 1626/4885NPC1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.